NMC

NEA Management Company’s CRISPR Therapeutics CRSP Stock Holding History

Quarter	Market Value	Status	Shares	Shares Change %	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$77.2M	Hold	1,587,854	–	–	5.81%	5
2025 Q1	$54M	Hold	1,587,854	–	–	4.16%	8
2024 Q4	$62.5M	Hold	1,587,854	–	–	3.53%	9
2024 Q3	$74.6M	Hold	1,587,854	–	–	4.06%	8
2024 Q2	$85.8M	Hold	1,587,854	–	–	6.45%	6
2024 Q1	$180M	Hold	1,587,854	–	–	11.2%	2
2023 Q4	$99.4M	Hold	1,587,854	–	–	6.62%	6
2023 Q3	$72.1M	Hold	1,587,854	–	–	5.57%	5
2023 Q2	$89.1M	Hold	1,587,854	–	–	6.8%	4
2023 Q1	$71.8M	Hold	1,587,854	–	–	4.96%	7
2022 Q4	$64.5M	Sell	1,587,854 -2,148	-0.1%	-$87.3K	3.63%	10
2022 Q3	$104M	Hold	1,590,002	–	–	5.19%	6
2022 Q2	$96.6M	Hold	1,590,002	–	–	4.96%	5
2022 Q1	$366M	Hold	1,590,002	–	–	10.56%	4
2021 Q4	$120M	Hold	1,590,002	–	–	2.44%	8
2021 Q3	$178M	Hold	1,590,002	–	–	2.11%	7
2021 Q2	$257M	Hold	1,590,002	–	–	3.35%	4
2021 Q1	$194M	Hold	1,590,002	–	–	4.35%	6
2020 Q4	$243M	Hold	1,590,002	–	–	6.43%	4
2020 Q3	$133M	Sell	1,590,002 -500,676	-24%	-$41.9M	5.63%	4
2020 Q2	$154M	Hold	2,090,678	–	–	6.18%	6
2020 Q1	$88.7M	Hold	2,090,678	–	–	4.63%	7
2019 Q4	$127M	Hold	2,090,678	–	–	6.02%	5
2019 Q3	$85.7M	Hold	2,090,678	–	–	7.1%	4
2019 Q2	$98.5M	Hold	2,090,678	–	–	6.9%	4
2019 Q1	$74.7M	Hold	2,090,678	–	–	3.88%	8
2018 Q4	$59.7M	Hold	2,090,678	–	–	2.37%	9
2018 Q3	$92.7M	Hold	2,090,678	–	–	4%	8
2018 Q2	$123M	Sell	2,090,678 -1,393,786	-40%	-$81.9M	5.76%	7
2018 Q1	$159M	Buy	3,484,464 +263,736	+8%	+$12.1M	7.08%	2
2017 Q4	$75.6M	Hold	3,220,728	–	–	3.13%	10
2017 Q3	$57.6M	Hold	3,220,728	–	–	2.02%	12
2017 Q2	$51.6M	Hold	3,220,728	–	–	1.88%	11
2017 Q1	$70.1M	Hold	3,220,728	–	–	2.44%	7
2016 Q4	$65.3M	Buy	+3,220,728	New	+$65.3M	2.59%	8